Biotechnology

Representative Patents and Published Applications

  • U.​​​S. Patent 10,766,968 – Methods and Compositions Relating to Anti-CHI3L1 Antibody Reagents to Treat Cancer (Assignee: Brown University)
  • U.S. Patent 10,752,700 – Methods and Compositions Relating to Anti-CHI3L1 Antibody Reagents to Treat Nonalcoholic Steatohepatitis (NASH), Nonalcoholic Fatty Liver Disease (NFALD) or Metabolic Syndrome (Assignee: Brown University)
  • U.S. Patent 10,745,435 – Nucleic Acid Prodrugs (Assignee: Cerecor, Inc.)
  • U.S. Patent 10,632,225 – Surgical Sutures Incorporated with Stem Cells or Other Bioactive Materials (Assignee: Bioactive Surgical, Inc.)
  • U.S. Patent 10,619,211 – Methods Using DNA Methylation for Identifying a Cell or a Mixture of Cells for Prognosis and Diagnosis of Diseases, and for Cell Remediation Therapies (Assignees: Brown University; The Regents of the University of California)
  • U.S. Patent 10,619,155 – Methods for Labeling and Manipulating a Cellular Circuit (Assignee: Brown University)
  • U.S. Patent 10,253,111 – Methods and Compositions Relating to Anti-CHI3L1 Antibody Reagents (Assignee: Brown University)
  • U.S. Patent 9,512,199 – Fibronectin Cradle Molecules and Libraries Thereof (Assignees: Novartis AG; University of Chicago)°
  • U.S. Patent 9,428,583 – Compositions and Methods of Use for Therapeutic Low Density Lipoprotein-Related Protein 6 (LRP6) Multivalent Antibodies (Assignee: Novartis AG)°
  • U.S. Patent 9,296,826 – Antibodies and Methods for WNT Pathway-Related Diseases (Assignee: Novartis AG)°
  • U.S. Patent 9,296,813 – Compositions and Methods of Use for Antibodies of Dickkopf-1 (Assignee: Novartis AG)°
  • U.S. Patent 9,296,810 – Fibronectin-Based Binding Molecules and Uses Thereof (Assignee: Novartis AG)°
  • U.S. Patent 9,290,573 – Therapeutic Low Density Lipoprotein-Related Protein 6 (LRP6) Multivalent Antibodies (Assignee: Novartis AG)°
  • U.S. Patent 9,192,663 – Antibodies for Epidermal Growth Factor Receptor 3 (HER3) (Assignee: Novartis AG)°
  • U.S. Patent 8,877,909 – Optimized Oligonucleotides and Methods of Using Same for the Detection, Isolation, Amplification, Quantitation, Monitoring, Screening, and Sequencing of Group B Streptococcus (Assignee: Intelligent Medical Devices, Inc.)°
  • U.S. Patent 8,815,246 – Fc Receptor Binding Proteins (Assignees: Dyax Corp.; Syntonix Pharmaceuticals, Inc.)°
  • U.S. Patent 8,758,996 – Optimized Probes and Primers and Methods of Using Same for the Binding, Detection, Differentiation, Isolation and Sequencing of Influenza A; Influenza B; Novel Influenza A/H1N1; and a Novel Influenza A/H1N1 RNA Sequence Mutation Associated with Oseltamivir Resistance (Assignee: Intelligent Medical Devices, Inc.)°
  • U.S. Patent 8,663,629 – Kallikrein-Binding “Kunitz Domain” Proteins and Analogues Thereof (Assignee: Dyax Corp.)°
  • U.S. Patent Application 2013/0090374 – Methods for the Treatment of Tay-Sachs Disease, Sandhoff Disease, and GM1-Gangliosidosis (Applicant: National Tay-Sachs & Allied Diseases Associations Inc.)°
  • U.S. Patent 7,993,896 – Streptomyces griseoplanus alpha‑Galactosidases for Removing Immunodominant alpha‑Galactose Monosaccharides from Blood Group B or AB Reactive Cells (Assignee: Velico Medical, Inc.)°
  • U.S. Patent 7,951,552 – Method of Preparing Non-Human Tissues for Xenotransplantation Using alpha‑Galactosidase (Assignee: Velico Medical, Inc.)°
  • U.S. Patent 7,943,820 – Genetically-Modified Plants Producing Lactosylceramide and Utilization Thereof (Assignee: National Institute of Advanced Industrial Science and Technology)°
  • U.S. Patent 7,884,184 – Regulatory T Cell Epitopes, Compositions and Uses Thereof (Assignee: EpiVax, Inc.)°
  • U.S. Patent 7,858,295 – Methods for Prolonging Survival of Platelets Using UDP-Galactose (Assignee: Velico Medical, Inc.)°
  • U.S. Patent 7,795,024 – Apparatus and Methods for Amplification of Blood Stem Cell Numbers (Assignee: Insception Bioscience, Inc.)°
  • U.S. Patent 7,767,415 – Compositions and Methods for Modifying Blood Cell Carbohydrates (Assignee: Velico Medical, Inc.)°
  • U.S. Patent 7,399,583 – Method for the Identification of Inhibitors of the Binding of ARE-Containing mRNA and a HuR Protein (Assignee: Novartis AG)°
  • U.S. Patents 7,384,912  and 7,015,195– Treatment of Bone Disorders with Skeletal Anabolic Drugs (Assignee: Osteotrophin, LLC)°
  • U.S. Patent 7,029,877 – Methods and Reagents for Protease Inhibition (Assignee: Novartis AG)°
  • U.S. Patent 6,924,106 – Rifamycin Biosynthesis Gene Cluster (Assignee: Novartis AG)°
  • U.S. Patent 6,833,255 – Drosophila melanogaster p70S6 Kinase (Assignee: Novartis AG)°
  • U.S. Patent 6,610,539 – Antisense Oligonucleotide Sequences as Inhibitors of Microorganisms (Assignee: GeneSense Technologies, Inc.)°
  • U.S. Patent 6,607,730 – Chlamydia Antigens and Corresponding DNA Fragments and Uses Thereof (Assignee: Aventis Pasteur, Ltd.)°
  • U.S. Patent 6,207,804 – Genetically-Engineered Antibody Analogues and Fusion Proteins Thereof (Assignee: Curis, Inc.)°
  • U.S. Patent 6,090,544 – Methods and Compositions for Identifying Morphogen Analogs (Assignee: Creative BioMolecules, Inc.)°
  • U.S. Patent 5,989,910 – Potent Genetic Switch Allowing Regulated Gene Expression in Eukaryotic Cells (Assignee: Université de Lausanne)°

°Denotes representations that were handled by a member of Adler’s Life Sciences team prior to joining Adler Pollock & Sheehan, P.C.

Back to Top